NEW YORK ─ Sema4 said on Wednesday that it has secured approval from the New York State Department of Health to conduct its Sema4 Signal Whole Exome/Transcriptome Sequencing (WES/WTS) and PanCancer somatic tests.
The firm said it believes it is the first company with a commercial laboratory to be approved by the NYS DOH for WES/WTS for solid and hematologic malignancies using tumor-normal analysis.